EURneffy: Nasal Adrenaline Spray for Anaphylaxis. Would you want to switch to EURneffy or continue with your Adrenaline Autoinjector (AAI)?

The approval of EURneffy in USA, Europe and now the UK was based on dosing with EURneffy resulting in similar blood levels of adrenaline to that seen with IM adrenaline injection, and similar (but not identical) changes in blood pressure and heart rate (something referred to as bioequivalence). BSACI notes that bioequivalence data (blood adrenaline levels and blood pressure) are not replacements for controlled clinical efficacy data. The adrenaline autoinjectors in current use were also approved without randomised controlled studies. Data relating to the effectiveness for EURneffy are limited to the following real-world data:

• A report of 15 children reacting at food challenge, 8 of whom had anaphylaxis (WAO definition).

• An uncontrolled case series of 545 patients (age range not specified) having allergic symptoms during oral food challenge or allergen immunotherapy, reported in a press release from the manufacturer dated 8th September 2025.9 Four hundred and eighty-six (486, or 89%) of 545 patients were effectively treated with a single dose of EURneffy, although it is not clear what proportion of these were having anaphylaxis according to the WAO or UK definitions.

For more information on the BSACI statement follow this link? https://www.bsaci.org/bsaci-eurneffy-statement/